Corvus Pharmaceuticals (CRVS) Cash & Equivalents (2015 - 2026)

Corvus Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 702.2% year-over-year to $40.1 million in Q1 2026; TTM through Mar 2026 was $40.1 million, a 702.2% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, down 47.64% from the prior year.
• Cash & Equivalents climbed to $40.1 million in Q1 2026 per CRVS's latest filing, from $4.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $40.1 million in Q1 2026 and bottomed at $2.9 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $12.6 million (2023), against an average of $14.7 million.
• Across the five-year window, Cash & Equivalents sank 79.26% in 2022 and soared 702.2% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $13.2 million in 2022, then decreased by 4.1% to $12.6 million in 2023, then plunged by 30.74% to $8.7 million in 2024, then tumbled by 47.64% to $4.6 million in 2025, then soared by 776.35% to $40.1 million in 2026.
• Per Business Quant, the three latest CRVS Cash & Equivalents figures stand at $40.1 million (Q1 2026), $4.6 million (Q4 2025), and $2.9 million (Q3 2025).